Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
Sponsor: Alixer Nexgen Therapeutics Limited
Summary
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
Official title: A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber/EEC
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
164
Start Date
2025-10-17
Completion Date
2026-04
Last Updated
2025-10-22
Healthy Volunteers
Yes
Conditions
Interventions
ALDP001 Nasal Spray
Experimental Arm
Placebo Nasal spray
Controlled arm
Locations (1)
Cliantha Research
Mississauga, Ontario, Canada